262 related articles for article (PubMed ID: 21119198)
1. Development and characterization of high affinity leptins and leptin antagonists.
Shpilman M; Niv-Spector L; Katz M; Varol C; Solomon G; Ayalon-Soffer M; Boder E; Halpern Z; Elinav E; Gertler A
J Biol Chem; 2011 Feb; 286(6):4429-42. PubMed ID: 21119198
[TBL] [Abstract][Full Text] [Related]
2. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist.
Niv-Spector L; Shpilman M; Boisclair Y; Gertler A
Protein Expr Purif; 2012 Feb; 81(2):186-92. PubMed ID: 22040607
[TBL] [Abstract][Full Text] [Related]
3. Novel superactive leptin antagonists and their potential therapeutic applications.
Gertler A; Elinav E
Curr Pharm Des; 2014; 20(4):659-65. PubMed ID: 23688008
[TBL] [Abstract][Full Text] [Related]
4. Pegylated Human Leptin D23L Mutant-Preparation and Biological Activity In Vitro and In Vivo in Male ob/ob Mice.
Gertler A; Solomon G
Endocrinology; 2019 Apr; 160(4):891-898. PubMed ID: 30802285
[TBL] [Abstract][Full Text] [Related]
5. Large-scale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as potent antagonists.
Salomon G; Niv-Spector L; Gussakovsky EE; Gertler A
Protein Expr Purif; 2006 May; 47(1):128-36. PubMed ID: 16289983
[TBL] [Abstract][Full Text] [Related]
6. Preparation of Potent Leptin Receptor Antagonists and Their Therapeutic Use in Mouse Models of Uremic Cachexia and Kidney Fibrosis.
Mak RH; Cheung WW; Solomon G; Gertler A
Curr Pharm Des; 2018; 24(9):1012-1018. PubMed ID: 29366406
[TBL] [Abstract][Full Text] [Related]
7. Pegylated leptin antagonist with strong orexigenic activity in mice is not effective in chickens.
Gertler A; Shinder D; Yosefi S; Shpilman M; Rosenblum CI; Ruzal M; Seroussi E; Friedman-Einat M
J Exp Biol; 2014 Jan; 217(Pt 2):180-4. PubMed ID: 24115063
[TBL] [Abstract][Full Text] [Related]
8. A superactive leptin antagonist alters metabolism and locomotion in high-leptin mice.
Chapnik N; Solomon G; Genzer Y; Miskin R; Gertler A; Froy O
J Endocrinol; 2013 Jun; 217(3):283-90. PubMed ID: 23482705
[TBL] [Abstract][Full Text] [Related]
9. Effect of peripherally administered leptin antagonist on whole body metabolism and bone microarchitecture and biomechanical properties in the mouse.
Solomon G; Atkins A; Shahar R; Gertler A; Monsonego-Ornan E
Am J Physiol Endocrinol Metab; 2014 Jan; 306(1):E14-27. PubMed ID: 24169045
[TBL] [Abstract][Full Text] [Related]
10. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity.
Elinav E; Niv-Spector L; Katz M; Price TO; Ali M; Yacobovitz M; Solomon G; Reicher S; Lynch JL; Halpern Z; Banks WA; Gertler A
Endocrinology; 2009 Jul; 150(7):3083-91. PubMed ID: 19342450
[TBL] [Abstract][Full Text] [Related]
11. Effects of high affinity leptin antagonist on prolactin receptor deficient male mouse.
Carré N; Solomon G; Gertler A; Binart N
PLoS One; 2014; 9(3):e91422. PubMed ID: 24667351
[TBL] [Abstract][Full Text] [Related]
12. Central leptin signaling deficiency induced by leptin receptor antagonist leads to hypothalamic proteomic remodeling.
Mazuecos L; Artigas-Jerónimo S; Pintado C; Gómez O; Rubio B; Arribas C; Andrés A; Villar M; Gallardo N
Life Sci; 2024 Jun; 346():122649. PubMed ID: 38626868
[TBL] [Abstract][Full Text] [Related]
13. The molecular mechanism of action of superactive human leptin antagonist (SHLA) and quadruple leptin mutein Lan-2 on human ovarian epithelial cell lines.
Fiedor E; Gregoraszczuk EŁ
Cancer Chemother Pharmacol; 2016 Sep; 78(3):611-22. PubMed ID: 27480179
[TBL] [Abstract][Full Text] [Related]
14. Leptin-induced downregulation of the rat hippocampal somatostatinergic system may potentiate its anorexigenic effects.
Perianes-Cachero A; Burgos-Ramos E; Puebla-Jiménez L; Canelles S; Viveros MP; Mela V; Chowen JA; Argente J; Arilla-Ferreiro E; Barrios V
Neurochem Int; 2012 Dec; 61(8):1385-96. PubMed ID: 23073237
[TBL] [Abstract][Full Text] [Related]
15. Identification of the hydrophobic strand in the A-B loop of leptin as major binding site III: implications for large-scale preparation of potent recombinant human and ovine leptin antagonists.
Niv-Spector L; Gonen-Berger D; Gourdou I; Biener E; Gussakovsky EE; Benomar Y; Ramanujan KV; Taouis M; Herman B; Callebaut I; Djiane J; Gertler A
Biochem J; 2005 Oct; 391(Pt 2):221-30. PubMed ID: 15952938
[TBL] [Abstract][Full Text] [Related]
16. A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo.
Catalano S; Leggio A; Barone I; De Marco R; Gelsomino L; Campana A; Malivindi R; Panza S; Giordano C; Liguori A; Bonofiglio D; Liguori A; Andò S
J Cell Mol Med; 2015 May; 19(5):1122-32. PubMed ID: 25721149
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.
Singh UP; Singh NP; Guan H; Busbee B; Price RL; Taub DD; Mishra MK; Fayad R; Nagarkatti M; Nagarkatti PS
Int Rev Immunol; 2014 Jan; 33(1):23-33. PubMed ID: 23841494
[TBL] [Abstract][Full Text] [Related]
18. Technical note: Effects of pegylation and route of administration on leptin kinetics in newborn lambs1.
Ramos-Nieves JM; Giesy SL; Schwark WS; Gertler A; Boisclair YR
J Anim Sci; 2019 Sep; 97(9):3768-3775. PubMed ID: 31250023
[TBL] [Abstract][Full Text] [Related]
19. ENU mutagenesis identifies mice with morbid obesity and severe hyperinsulinemia caused by a novel mutation in leptin.
Hong CJ; Tsai PJ; Cheng CY; Chou CK; Jheng HF; Chuang YC; Yang CN; Lin YT; Hsu CW; Cheng IH; Chen SY; Tsai SJ; Liou YJ; Tsai YS
PLoS One; 2010 Dec; 5(12):e15333. PubMed ID: 21151569
[TBL] [Abstract][Full Text] [Related]
20. PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy.
Morath V; Bolze F; Schlapschy M; Schneider S; Sedlmayer F; Seyfarth K; Klingenspor M; Skerra A
Mol Pharm; 2015 May; 12(5):1431-42. PubMed ID: 25811325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
